MET and non-small cell lung carcinoma: Previous studies showed that acquired resistance to EGFR inhibitors was associated with gene amplification of c-MET in NSCLC [49], suggesting that combined targeting of EGFR and c-MET could be beneficial to overcome the onset of drug resistance.